# PTK/ZK in Disseminated Malignant Melanoma

> **NCT00615160** · PHASE1,PHASE2 · TERMINATED · sponsor: **Michael Weichenthal** · enrollment: 9 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** PTK787/ZK 222584
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT00615160
- **Lead sponsor:** Michael Weichenthal
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Substance was withdrawn from further development.
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00615160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00615160, "PTK/ZK in Disseminated Malignant Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00615160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*